News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
1Bitget UEX Daily | US-Iran Talks Remain Divided but Ceasefire Expectations Boost US Stocks; Google Releases Cache Compression Technology Impacting Storage Sector (March 26, 2026)2PDD Holdings 2025 Q4 Earnings: Growth Significantly Slows, Full Bet on Supply Chain Investment to Build the "New Pinduoduo"3Hard to go long, hard to go short! Nomura strategist: "Current macro volatility, trading poses career risks"; Goldman Sachs analyst: "Cash is king"
The Atlantic: The Supreme Court’s Humiliating Gift to Trump
美股ipo·2026/02/22 02:48
Shiba Inu: Why a short-term SHIB rally may follow 15% drop
AMBCrypto·2026/02/22 01:03
Altcoins Slow Their Slide Against Bitcoin as Market Shifts Toward Selective Growth
Cointurk·2026/02/22 00:51
Bitcoin vs. Gold: Long-Term Chart Signals Possible Bottom After 14-Month Relative Bear Market
BlockchainReporter·2026/02/21 23:00
Bitwise CIO Names 4 Crypto Assets to Own in 2026 as Bear Market Deepens
Coinpedia·2026/02/21 22:30
Bitcoin Bear Market Bottom or Another Leg Down? 5 Signals That Will Decide
Coinpedia·2026/02/21 22:30
Injective (INJ) Price Surges as Upgrade Approval and $2M Accumulation Reinforce Bullish Structure
Coinpedia·2026/02/21 22:30
Flash
12:30
In the week ending March 21, initial jobless claims in the United States were 210,000, in line with expectations.BlockBeats News: In the week ending March 21, initial jobless claims in the United States were 210,000, in line with expectations, with a previous value of 205,000. (Forex Factory)
12:28
VolitionRX Limited announced that its research abstract on lung cancer risk stratification has been officially released at the European Lung Cancer Congress.This research demonstrates the potential of using novel biomarkers for lung cancer risk stratification, providing important evidence for early diagnosis and personalized treatment. The publication of these results marks another significant advancement for the company in the field of tumor diagnosis.
12:28
According to a public SEC filing, biopharmaceutical company Dianthus Therapeutics Inc. (DNTH) is adjusting the enrollment criteria for the clinical trial of its core drug Claseprubart.The company plans to formally submit these amendment proposals to the U.S. Food and Drug Administration for review in the first quarter of 2026.
News